Menu

Safety guide · 2 min read

Livozo ranks sources, ties claims to them and corrects pages quickly.

The short answer

Livozo uses primary sources first, such as FDA labels and peer-reviewed trials, and links each medical claim to its source on the page. We are building a claim ledger that records every claim and its limits. A named medical reviewer is not yet engaged, so every page shows its medical review as pending until a clinician signs off.

Where our information comes from

We use sources in a fixed order. First come FDA labels, safety communications and official guidance. Next come NIH, CDC and other government sources, then peer-reviewed systematic reviews, guidelines and major trials.

Specialty-society guidance comes after that. We use partner documents only for operational facts, and we never use competitor pages as medical evidence.

The claim ledger

We are building a claim ledger for every medical page. Each entry will record the exact claim, the population, formulation, route and outcome, the source and the evidence grade. Until it is complete, each claim links to its source on the page.

If the evidence is about a different ingredient, dose, route or group of people, the page must say so next to the claim. For example, trials of branded GLP-1 medicines do not tell us how compounded versions perform, and our pages state that.

Review steps and who does them

Each page moves through the same steps: brief, writing, SEO edit, medical review, legal and compliance review, then accessibility and quality checks. After publishing, we recheck each page at 30, 90 and 180 days.

TODO(clinical): a named medical reviewer is not yet engaged. We will not invent a reviewer name or credential. Until an accountable reviewer is in place, pages show a pending review state, and each page will get medical review once one is engaged.

Updates, corrections and AI use

We update affected pages within one business day for FDA warnings, recalls, availability changes, partner changes or a material legal correction. FDA safety alerts, such as its warnings about unapproved GLP-1 drugs, are the kind of event that triggers this.[1]

We review pricing, availability, pharmacy and product-status facts at least monthly. When we correct a page, we update its date. If you spot an error or a side effect we should know about, tell us, and report side effects to FDA through MedWatch.[2]

We may use AI tools to help with research and drafting. A person checks every medical claim against its source before publishing.

What we know

  • Our pages follow a fixed source hierarchy that starts with FDA and other government sources.
  • Each medical claim is logged with its source, population and limits.
  • Urgent safety changes trigger updates within one business day.

What we don't know yet

  • When a named medical reviewer will be engaged. This is still pending.
  • How new evidence will change our current pages. We will update them as it arrives.
  • Whether every error has been caught. We ask readers to tell us when something looks wrong.

Safety

  • Our articles are general education, not medical advice for you.
  • For a medical emergency, call 911 or go to the nearest emergency room.

This guide is education, not medical advice. It does not create a clinician-patient relationship. If you think you are having an emergency, call 911.

Sources

  1. FDA — FDA's concerns with unapproved GLP-1 drugs used for weight loss
  2. FDA — MedWatch: the FDA safety information and adverse event reporting program

Keep reading.